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Abstract
Background: In the rural zone of Niakhar in Senegal, the first therapeutic failures for chloroquine
(CQ) were observed in 1992. In 2003, the national policy regarding first-line treatment of
uncomplicated malaria was modified, replacing CQ by a transitory bi-therapy amodiaquine/
sulphadoxine-pyrimethamine (AQ/SP), before the implementation of artemisinin-based
combination therapy (ACT) in 2006.
The aims of the study were to assess the evolution of anti-malarial prescriptions in three health
care facilities between 1992 and 2004, in parallel with increasing CQ resistance in the region.
Methods: The study was conducted in the area of Niakhar, a demographic surveillance site located
in a sahelo-sudanese region of Senegal, with mesoendemic and seasonal malaria transmission.
Health records of two public health centres and a private catholic dispensary were collected
retrospectively to cover the period 1992–2004.
Results: Records included 110,093 consultations and 292,965 prescribed treatments. Twenty-five
percent of treatments were anti-malarials, prescribed to 49% of patients. They were delivered all
year long, but especially during the rainy season, and 20% of patients with no clinical malaria
diagnosis received anti-malarials. Chloroquine and quinine represented respectively 55.7% and
34.6% of prescribed anti-malarials. Overall, chloroquine prescriptions rose from 1992 to 2000, in
parallel with clinical malaria; then the CQ prescription rate decreased from 2000 and was
concomitant with the rise of SP and the persistence of quinine use. AQ and SP were mainly used
as bi-therapy after 2003, at the time of national treatment policy change.
Conclusion: The results show the overall level of anti-malarial prescription in the study area for
a considerable number of patients over a large period of time. Even though resistance to CQ
rapidly increased from 1992 to 2001, no change in CQ prescription was observed until the early
2000s, possibly due to the absence of an obvious decrease in CQ effectiveness, a lack of therapeutic
options or a blind follow-up of national guidelines.
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Background
One of the main issues in worldwide management of
malaria is the occurrence of chemoresistance and its rapid
spread. Efforts to control and treat malaria have already
been seriously compromised, particularly by the resist-
ance of Plasmodium falciparum to chloroquine (CQ), then
to other drugs, such as sulphadoxine-pyrimethamine
(SP), mefloquine, and amodiaquine (AQ). Resistance to
chloroquine first appeared in South-East Asia (Thai-Cam-
bodian border) and in South America (Colombia and
Venezuela) in the late 1950s [1,2]. In Africa, it was first
reported in Kenya and Tanzania in 1978 [3-6]. It then
spread to other countries and to Centre and South Africa
[7-12], before reaching West Africa in 1983 [13-15]. By
1989, resistance was widespread in sub-Saharan Africa.
In the area of Niakhar in Senegal, first therapeutic failures
to CQ were observed in 1992 and chemoresistance then
progressively increased [16,17]. The public health impact
of chloroquine resistance was shown in many parts of
Africa [18] and a rise in malaria specific mortality, meas-
ured by verbal autopsy, was demonstrated in three rural
regions of Senegal (Mlomp, Bandafassi and Niakhar)[19],
where demographic and epidemiological surveillance was
particularly well developed. In Niakhar, a two-fold
increase in malaria mortality among children 0–9 years
was shown, from 4.0 to 8.2 per 1,000 children (0–9) per
year between the periods (1984–1991) and (1992–1995).
However, national policy concerning malaria treatment
did not change until 2003. A consensus conference held
by the Ministry of Health in June 2003 led to the replace-
ment of CQ by the transitory bi-therapy AQ/SP[20],
before the implementation of artemisinin-based combi-
nation therapy (ACT) using artesunate/amodiaquine (AS/
AQ) in 2006.
Data discussed in the present article concern a considera-
ble number of patients and prescriptions in three rural
health care facilities over a long period, from the emer-
gence of CQ resistance in 1992, until the treatment policy
change in 2003 and its application in health centres. An
attempt was made to assess the evolution of therapeutic
practices in peripheral health care facilities according to
the period of study and the dispensary.
The aim of the research was to study the evolution of anti-
malarial prescriptions in Niakhar area in the context of the
increase in CQ resistance estimated by surveys realized in
the region during the same period.
Methods
Study area and population
Niakhar study area
The study was conducted in the area of Niakhar, a sahelo-
sudanese zone located in the region and department of
Fatick, 130 kilometres south-east of Dakar, Senegal (N
14°30, W 16°30). A demographic surveillance site has
been implemented in this area in 1963 by the Institut de
Recherche pour le Développement (IRD, formerly
ORSTOM) and is currently composed of 30 villages [21].
The zone covers 230 km2. It had 26,356 inhabitants on
the 1st January 1992 and 33,890 on the 1st January 2004,
mostly from the Sereer ethnic group and Muslim religion.
Malaria transmission in the area is endemic and occurs
principally from August to November, following the rainy
season from July to October.
Health care facilities
Three health care facilities are located in the villages of
Diohine, Toucar and Ngayokhem, which are among the
most populated villages of the area (3,311, 3,686 and
2,332 inhabitants in 2004 respectively). Patient manage-
ment is carried out in Diohine by a private catholic dis-
pensary, in Toucar and Ngayokhem by public health
centres. All of them include basic health services: curative
and prenatal care, deliveries, and vaccination. The health
centre is managed by a nurse, usually assisted by a com-
munity health worker, a treatment seller and when possi-
ble a midwife or a matron, and trainees. At the time of the
study, the diagnosis of malaria was based on clinical signs
only as parasitological confirmation by thick smear or
rapid test could not be performed.
Analysis methods
Records from the three health care facilities provided data
about clinical diagnosis and anti-malarial prescriptions.
They were filled in routinely by the nurse during consulta-
tions with patients and included only outpatient cases.
Registers covering the period 1992–2004 were collected
retrospectively from the health centres and entered on
dBase IV software (dataBased Intelligence, Inc., Vestal,
NY, USA) by the data entry staff in Niakhar and Dakar.
The analysis was performed using Stata 8.0 software
(StataCorp LP, Texas, USA).
Results
Between 1992 and 2004, the total number of prescribed
treatments was 292,965, corresponding to 110,093
patients. Among all treatments, 73,779 were anti-malarial
drugs (25.2%).
Anti-malarial prescriptions
Anti-malarials were prescribed to 53,391 patients
(48.5%), although malaria was clinically diagnosed in
only 39,998 (74.9%) of them (Table 1). Anti-malarialsMalaria Journal 2009, 8:83 http://www.malariajournal.com/content/8/1/83
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were prescribed to 92.5% of patients with presumptive
malaria and to 19.8% of patients with other diagnoses.
Between 1992 and 2004, the monthly average number of
prescribed anti-malarials was 461, versus 1,406 in the
month of October alone. Sixty-two percent of all anti-
malarials were prescribed during the four month-period
of the rainy season (August to November) (Figure 1).
Chloroquine
CQ was prescribed to 41,103 patients (77.0% of patients
who received anti-malarials), of which 29,452 (71.7%)
had clinical malaria. It represented 55.7% of the pre-
scribed anti-malarials. Figure 2 shows the evolution of CQ
prescriptions from 1992 to 2004. CQ was given to an aver-
age of 3,162 patients per year, with differences according
to the period of study.
From 1992 to 1996, CQ prescriptions rose progressively,
in parallel with the diagnoses of clinical malaria. In 1997,
a drop in both indicators occurred; then from 1998 to
2000, morbidity and prescriptions increased again. From
2000 to 2004, there was a dissociation between presump-
tive malaria morbidity and CQ prescriptions: the number
of clinical malaria cases continued to increase, while CQ
Table 1: Anti-malarial prescriptions to all patients, presumptive malarial and non-malarial patients.
no of prescribed AM* % no of patients receiving AM % malarial patients % non-malarial patients§ %
total AM* 73 779 100 53 391 100 39 998 74.9 12 656 23.7
CQ1(total) 41 103 55.7 41 103 77.0 29 452 71.7 11 058 26.9
Q2(total) 25 546 34.6 25 546 47.8 23 783 93.1 1 570 6.1
CQ+Q3 16 391 22.2 16 391 30.7 15 608 95.2 717 4.4
SP4(total) 3 785 5.1 3 785 7.1 3 275 86.5 487 12.9
AQ5(total) 3 335 4.5 3 335 6.2 2 845 85.3 487 14.6
AQ+SP6 1 828 2.5 1 828 3.4 1 658 90.7 168 9.2
*AM: Anti-malarials, §patients with unknown clinical diagnosis are excluded.
1CQ (total): total number of chloroquine treatments (CQ prescribed alone and CQ+Q), 2Q (total): total number of quinine treatments (Q 
prescribed alone and CQ+Q), 3CQ+Q: CQ and Q prescribed together (Q as first treatment and CQ as relay treatment), 4SP (total): total number 
of sulphadoxine-pyrimethamine treatments, 5AQ (total): total number of amodiaquine treatments, 6AQ+SP: bi-therapy with AQ and SP.
Seasonality of anti-malarial prescriptions in health care facilities, Niakhar area, Senegal (1992–2004) Figure 1
Seasonality of anti-malarial prescriptions in health care facilities, Niakhar area, Senegal (1992–2004). Green, 
orange, blue and pink lines represent the mean number of prescriptions per month between 1992 and 2004, concerning chlo-
roquine (CQ), quinine (Q), sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) respectively.Malaria Journal 2009, 8:83 http://www.malariajournal.com/content/8/1/83
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prescriptions started to decrease. Then, the number of
malarial patients also declined and the drop in CQ pre-
scriptions became steeper (in 2001–2004).
Other anti-malarial prescriptions
Quinine injections accounted for 34.6% of all prescribed
anti-malarials; AQ and SP represented 4.5% and 5.1%
respectively. Halofantrine was prescribed to six patients.
Among the 53,391 patients treated by anti-malarials,
47.8% received quinine, 6.2% AQ and 7.1% SP; 3.4%
received the AQ/SP bi-therapy (Table 1). Quinine pre-
scriptions followed the same tendency as CQ until 1999.
When CQ prescriptions started to decrease from 2000 to
2004, the use of quinine remained high and followed
clinical malaria morbidity.
Concerning AQ and SP, a few prescriptions of either drug
occurred sporadically before 2003 (e.g. AQ in 1996 and
SP since 1999), but they were mainly prescribed together
as a bi-therapy from 2003 onwards, following the new
national policy. Overall, the rise of other anti-malarials
prescriptions (quinine, SP) was concomitant with the
decline in CQ use.
Evolution of chloroquine prescriptions in health centres 
according to chemoresistance in the study area
Figure 3 presents the trends in the proportion of patients
receiving CQ prescriptions among all anti-malarials
between 1992 and 2004. From 1992 to 1997, the propor-
tion of patients treated with CQ remained high (on aver-
age, 91% of patients receiving anti-malarials), then it
decreased slightly from 1998 to 2000 (on average, 83%).
The relative decrease of CQ prescriptions was more
marked from 2001 and it confirms the tendencies dis-
played on Figure 2.
In parallel, there was an increase of chemoresistance in
the region. Thanks to a careful surveillance of the area, the
absence of resistance to CQ seemed proven until 1990
[22]. Although no suspicion of resistance was mentioned
in the area of Niakhar, appearance of resistances or thera-
peutic failures of malaria to this drug in other areas of Sen-
egal led to estimate chemosensitivity by relevant surveys.
During the period of study, in vivo and  in vitro tests
showed a gradual increase of the resistance of P. falciparum
to CQ in the area, going from 10% in 1993 to a maximum
of 42% in 2001 [16,17,23,24].
Evolution of presumptive malaria cases and anti-malarial prescriptions in health care facilities, Niakhar area, Senegal (1992– 2004) Figure 2
Evolution of presumptive malaria cases and anti-malarial prescriptions in health care facilities, Niakhar area, 
Senegal (1992–2004). The black line represents the annual number of presumptive malaria cases. Green, orange, blue and 
pink lines represent the annual number of prescriptions of chloroquine (CQ), quinine (Q), sulphadoxine-pyrimethamine (SP) 
and amodiaquine (AQ) respectively.
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National policy change and anti-malarial treatment 
according to health care facilities
The new bi-therapy (AQ/SP) replaced CQ in health care
facilities between 2003 and 2004. In 2004, overall CQ use
accounted for 271 out of 3,370 (8%) patients being pre-
scribed anti-malarial drugs, but figures varied considera-
bly between dispensaries. In Toucar, no CQ was used that
year, whereas 48 patients (6.4%) were still prescribed CQ
in Ngayokhem, predominantly concentrated at the begin-
ning of the year from January to March, and 223 (39.4%)
in Diohine, distributed throughout the year.
The evolution of AQ/SP bi-therapy the same year also
showed various results: overall prescription accounted for
1,653 patients in 2004 (49.1% of patients receiving anti-
malarials), ranging from 3 (0.5%) in Diohine to 127
(17.0%) in Ngayokhem and 1,523 (74.1%) in Toucar.
Concerning quinine, 1,766 patients (52.4%) received
injections in 2004: in Ngayokhem the majority of patients
being prescribed anti-malarials were treated with quinine
(525/749; 70.1%), 284 out of 566 (50.2%) in Diohine,
and 957 out of 2 055 (46.6%) in Toucar.
In 2004, AQ and SP were still used as monotherapy in
respectively 502 (15%) and 468 (14%) patients. SP was
prescribed alone to 43% of patients receiving anti-malari-
als in Diohine and 25% in Ngayokhem. In Toucar, AQ
monotherapy was delivered to 20% of patients who were
prescribed anti-malarials.
Discussion
As this observational study was held on a highly popu-
lated and closely observed demographic study site, it
allowed the collection of data on more than 100,000
patients over 13 years, when important changes in
malaria control policy were undertaken.
Anti-malarials represented 25% of all prescribed treat-
ments and concerned nearly half of the patients consult-
ing in the health care facilities. Among these treated
patients, one fourth was not clinically diagnosed as
malaria.
Limits of the method: reliability of data
Data rely on information reported on health records.
These registers are usually filled in by the nurse during
outpatient's consultation. They are useful for clinical fol-
low-up of the patients and for public health statistics but
they are not adapted to research purposes. This lack of
data precision is inherent to retrospective studies, which
are based on passive data collection conducing to inevita-
ble loss of information. During analysis, inconsistent and
missing data had to be dealt with. Missing data may either
Evolution of chloroquine resistance rate and proportion of patients with CQ prescriptions between 1992 and 2004 in Niakhar  area Figure 3
Evolution of chloroquine resistance rate and proportion of patients with CQ prescriptions between 1992 and 
2004 in Niakhar area. Green line represents the proportion of patients receiving CQ prescriptions among all patients being 
prescribed anti-malarials (AM) (%). Red bars represent the rate of CQ resistance (%). (a) 1993, 1994, and 1995 estimates: in 
vivo chemosensitivity studies conducted in Diohine village, Niakhar area, Fatick region [16]. (b) 1998 and 2001 estimates: in vivo 
studies conducted in Kaolack sentinel site, 50 kilometres from Fatick [17].
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come from the record itself, when no treatment has been
mentioned by the nurse, or may be due to errors in data
entry.
Data about malaria morbidity refer only to clinically diag-
nosed patients attending health centres, as confirmation
of suspected cases was not routinely realized in peripheral
health care facilities. Even though these presumptive
malaria cases certainly overestimate real malaria morbid-
ity, it is probably not related with the changes in trends
during the time of observation and one may assume that
overestimation was constant over the period.
Interpretation of data
Overall trends in anti-malarial prescriptions
A large proportion of patients were treated with anti-
malarials, although malaria was not confirmed parasito-
logically in most cases. This was due to the policy regard-
ing management of patients in malaria endemic regions,
before the introduction, in 2007, of rapid diagnostic tools
to confirm malaria diagnosis. Until 2003, management of
the patients consisted in early diagnosis and treatment at
the health care facility or home-based treatment of fevers
with CQ. In health centres, suspected cases of uncompli-
cated malaria were treated with CQ whereas quinine had
to be saved for severe cases. Actually, health agents did not
always comply with official guidelines and anti-malarials
were extensively used. Frequently, patients suffering from
another disease received anti-malarial drugs as well
(19.8% in this study), usually CQ, as a "precautionary
principle". Besides, quinine was not used for severe cases
only.
Even if anti-malarials were prescribed throughout the year
for a great number of patients, their use was mainly con-
centrated during the rainy season. Seasonality of prescrip-
tions followed malaria morbidity patterns in this
mesoendemic area, where malaria transmission occurs
principally in a four-month period, leading to a rise in
malaria cases between August and December, with a peak
in the month of October. Presumptive malaria cases rep-
resented approximately 40% of total attendance through
the observed period.
After a period of increasing clinical malaria cases and CQ
prescriptions from 1992 to 1996, a sudden drop of pre-
scriptions was observed in 1997, following the fall in con-
sultations the same year in the health care facilities (Figure
2). Two explanations are proposed. First, rainfall was
lower in 1997 than in the previous years (419 mm precip-
itations vs a yearly average of 522 mm during 1992–1996,
as recorded in the Niakhar station by our own rain
gauges), which may have reduced malaria transmission
and, therefore, the morbidity attributable to malaria. Sec-
ond, the immunization trials conducted until 1997 may
have played a motivating role on the sanitary activities
during the preceding years [21,25] inducing a high level of
prescriptions. Other drug prescriptions also decreased by
10–20% between 1996 and 1997, associated to a decline
in medical consultations.
Until the late 1990s, health workers did not change their
practices because either they have not realized there was a
rise in CQ resistance, as CQ decreasing effectiveness was
not obvious, or they have lacked other therapeutic
options. Besides, an additional study (Munier et al,  in
press) showed an absence of significant increase in
patients' returns to the health centre after anti-malarial
treatment over the period of study, which is not in favour
of a perception of CQ decreasing effectiveness at the dis-
pensary level.
In the early 2000s, the slight decrease in CQ prescription
was concomitant with the persistence of the use of qui-
nine at a high level and the rise of SP prescription. It could
be attributed to a better awareness of the growing resist-
ance of P. falciparum, which may have become clinically
apparent, prompting health agents to opt for alternative
drugs (SP or quinine). Another hypothesis is that health
care providers anticipated the implementation of the new
policy. Being aware of discussions held at national and
local levels about the change of anti-malarial strategy,
they may have started to change their practices before the
new policy was adopted. Finally, patients' complaints,
such as itching and eye allergies, intensified after the
National Pharmacy liberalized the CQ sources of supply,
possibly due to the presence of different excipients in
these products that would be less tolerated by patients.
This may have incited prescribers to use alternative drugs.
At that time, they could also order cheaper generic SP at
the health district (Maloxine®), compared to the Fansidar®
proprietary drug.
Furthermore, contrary to CQ, interest in quinine
remained stable in this area. As it is known to be very
effective, patients often request injections and they even
seek them from other providers, when they cannot get
them at the dispensary [20]. Thus health agents made an
excess use of quinine.
As the delivery of drugs to the facility was dependant on
the drug policy, the new directive was followed by the
abrupt drop of CQ prescription in 2003–2004 (Figures 2
and 3) and the use of AQ and SP prescribed in association.
Therapeutic practices according to the health care facility
Beyond the general tendency, use of anti-malarials was
highly variable according to the health centre, indicating
distinct therapeutic practices, especially in 2004 after the
change in national anti-malarial policy.Malaria Journal 2009, 8:83 http://www.malariajournal.com/content/8/1/83
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After the policy change, the National malaria control pro-
gramme recalled the remaining CQ stocks from public
health centres. However, some facilities finished their
own CQ stock before ordering the new anti-malarial
drugs. In any case, CQ was not supposed to be sold any-
more at the district pharmacy's level. While in Toucar the
national recommendations were followed thoroughly
and CQ delivery was stopped in 2004, the delay was
higher in the two other centres. In Ngayokhem, it seems
that there were remaining stocks of CQ, which were fur-
ther used during the dry season. The new efficacious drugs
started to be prescribed in the rainy season, when a high
increase of malaria morbidity was expected. Finally, in
privately-run Diohine, CQ was still prescribed in 2004 all
year long, although quinine prescriptions rose above CQ
during the rainy season. It may be explained by the con-
tinuing supply of CQ by a catholic organization, which
had not terminated its stocks. Only three patients received
AQ/SP bi-therapy. In Toucar, the attendance of the same
experienced nurse since 1996 is most probably a key fac-
tor in the respect of treatment guidelines.
Other practices outside official health care facilities, such
as self-medication and purchase of medicines via the par-
allel drug market may have played a role. Previous socio-
anthropological studies conducted in this rural zone [26-
28] have shown that these practices are associated with
complex behaviour resulting in a high proportion of
patients not attending modern health facilities. Even
though self-medication is generally the first response in
case of a child's fever, populations preferably use sympto-
matic than etiological treatment [26]. They also consid-
ered that CQ was more efficient in preventing than
treating malaria. A population-based survey conducted in
the same area in 2001 [28] showed that anti-malarials
represented only 18.2% of total self-medication (versus
64.7% for antipyretics). Furthermore, CQ was seldom
available on markets in the years preceding the policy
change, even though it was a cheap and affordable drug.
Actually, customers rarely asked about it, and for the
retailer, CQ was not profitable enough, being useful in a
three-month period only. To cure malaria, they rather
sold paracetamol or aspirin, which would treat the fever
symptom (Le Hesran and Baxerres, personal communica-
tion).
This health-seeking behaviour was present during the
entire period of study and probably does not interfere
with overall trends in anti-malarial prescriptions in health
care facilities, which represent the main anti-malarials
providers in this area.
Neither AQ nor SP was found on the parallel market until
2003. Shortly after the policy change, it was noticed that
some health workers in a neighbouring region [20] had
not been properly trained for the new policy and did not
always follow guidelines, prescribing AQ and SP in mon-
otherapy, or quinine injections.
Conclusion
Results reflected the overall level of CQ and other anti-
malarial prescription in this area, and showed that health
centres were the main providers of anti-malarials during
the period 1992–2004.
Paradoxically, in spite of the emergence of CQ resistance
in 1992, subjected to intense advertising in this highly-
medicalized area where clinical trials were then con-
ducted, no significant decrease in CQ prescription was
observed between 1992 and 2000 and overall practices
regarding malaria management changed slowly during
this time. This fact could be explained by the absence of
an obvious perceptible decrease in CQ effectiveness.
Moreover, in the absence of guidelines from the Ministry
of Health, therapeutic policy, stock clearance, and finan-
cial accessibility of CQ could be other plausible factors
explaining this result.
These data also highlight the low reactivity between the
appearance of chemoresistance and the change in
national anti-malarial treatment policy. Given the cost of
new anti-malarials was not affordable for a long time,
morbidity and mortality figures were not yet alarming,
and not to mention the poor administrative reactivity,
change in national strategy took time to take off.
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